Target-Controlled Infusion: Why TCI Should Be the Default for TIVA in 2026

From Research Tool to Standard of Care

When target-controlled infusion (TCI) was introduced in the 1990s, it was a research novelty. Anesthesiologists programmed a target plasma concentration into an infusion pump, and the pump automatically adjusted infusion rates to maintain that target. It was elegant in concept but impractical—the technology was clunky, the models were limited, and most operating rooms didn't have the infrastructure to support it.

Fast forward to 2026: TCI is standard practice in advanced centers worldwide. European guidelines recommend it. Anesthesiologists increasingly recognize it as superior to manual infusion. Yet adoption remains patchy. Many ICUs and operating rooms still rely on weight-based calculations and manual rate adjustments—a approach that introduces unnecessary variability and risk.

This article makes the case for why TCI should be the default, not the exception, for total intravenous anesthesia (TIVA) in 2026 and beyond.

Understanding Target-Controlled Infusion

Traditional TIVA relies on weight-based formulas. A patient weighing 70 kg receives a propofol induction dose of 1.5-2 mg/kg, which works out to 105-140 mg. Then a maintenance infusion of 6-12 mg/kg/hr is started manually, with adjustments based on observed depth of anesthesia and hemodynamics.

This approach has problems:

• Population-based dosing ignores individual variability. Age, lean body weight, organ function, and metabolism vary widely. A 70-year-old woman and a 30-year-old man of the same weight have dramatically different pharmacokinetics.
• Manual rate adjustments are reactive, not predictive. The anesthesiologist observes that the patient is "light" (moving, elevated heart rate) and increases the infusion. But there's a delay—it takes 10-20 minutes for plasma concentration to reach a new steady state. Reactivity induces overshoot and undershoot.
• Inter-individual variability is high. Studies show that maintaining a given plasma concentration with manual infusion can vary by 30-50% between patients, despite identical clinical appearance.

Target-controlled infusion solves these problems by using pharmacokinetic models—mathematical equations that predict how a drug distributes in the body based on plasma concentration, volume of distribution, and elimination rate.

The 19 Pharmacokinetic Models Available

One of TCI's greatest strengths is model diversity. Different populations have different pharmacokinetics—an elderly patient's propofol clearance is 25-40% lower than a young adult's. Rather than one-size-fits-all dosing, TCI accommodates this.

Propofol Models (most developed):

• Marsh (1991): The original model, based on a small population of young adults. Simple, but doesn't account for age or obesity.
• Schnider (1998/1999): Updated model accounting for age and lean body weight (PK model 1998, PD model 1999). More accurate for elderly and obese patients. Considered the gold standard for many years.
• Eleveld (2018): Most recent model, developed from 5,000+ patient data points. Accounts for age, lean body weight, height, gender, and disease state. Superior prediction in extreme populations (very elderly, very obese).
• Paedfusor: Specifically designed for pediatric populations.

Remifentanil Models:

• Minto (1997): The standard remifentanil model, accounting for age and weight.
• Eleveld Remifentanil (2018): Updated model with improved accuracy in obese and elderly patients.

Other Drugs Supported by TCI Systems (2026):

Etomidate (Diprifusor), Thiopental, Methohexital, Alfentanil, Sufentanil, Dexmedetomidine, Volatile anesthetics (when delivered IV), and emerging agents. The field is rapidly expanding.

The availability of 19 models across these drugs means anesthesiologists can choose the model best suited to their patient's physiology. A TCI pump programmed with the Eleveld model will deliver safer, more predictable anesthesia to an 85-year-old than the Marsh model.

Clinical Advantages of TCI Over Manual Infusion

1. Reduced Induction-to-Emergence Variability

When you program TCI to achieve a target plasma concentration, induction time and emergence time become predictable. A propofol target of 4 mcg/mL produces loss of consciousness in 30-60 seconds reliably. Reducing the target to 2 mcg/mL produces emergence in 5-10 minutes. This predictability improves operating room efficiency and reduces patient anxiety around anesthesia.

2. Reduced Drug Consumption

Because TCI maintains a specific concentration rather than infusing at a fixed rate, it uses less drug overall. Studies show 15-25% reduction in total drug use compared to manual infusion, while maintaining equivalent anesthetic depth. This reduces cost and exposure to drug side effects.

3. Superior Hemodynamic Stability

The reactive adjustments of manual infusion induce overshoot—the anesthesiologist sees low blood pressure, stops the infusion, blood pressure overshoots, then they restart. TCI avoids this by using predictive infusion adjusted continuously for changing plasma concentration. Hemodynamic stability improves, particularly in elderly and cardiovascularly-compromised patients.

4. Reduced Postoperative Cognitive Dysfunction

Excessive depth of anesthesia (over-sedation) is associated with postoperative cognitive dysfunction, delirium, and worse long-term outcomes in elderly patients. Because TCI maintains specific, adjustable targets, anesthesiologists can use lower concentrations than they might intuitively choose with manual infusion, reducing deep anesthesia-related complications.

5. Easier Titration in Complex Patients

For obese, elderly, or critically ill patients, determining the "right" infusion rate is difficult. TCI removes this guesswork. The anesthesiologist sets a target; the pump handles the complex pharmacokinetics.

ICU Adoption Challenges: Why It's Slow

If TCI is superior, why aren't all ICUs using it? Several barriers:

Nursing Familiarity

Nurses trained on manual infusion may distrust automated systems. "I can't see the ml/hr on the pump" is a common concern. Education and experience address this, but it requires institutional commitment.

Equipment and Software Costs

TCI-capable pumps are more expensive than basic infusion pumps. A hospital might spend $50,000-200,000 to upgrade their infusion fleet to TCI-capable systems.

Regulatory and Validation Burden

Implementing new pharmacokinetic models requires validation in the institutional population. This is rigorous work but essential for safety.

Resistance to Change

"We've been doing this successfully for 20 years." Inertia is powerful. But data is compelling enough that this resistance is weakening.

TCI in the ICU: The Future

ICU use of TCI is increasing but still uncommon. Most ICU sedation relies on fixed infusion rates of propofol or dexmedetomidine. Yet the same advantages apply: predictable sedation depth, reduced drug exposure, better stability.

As nurses gain familiarity with TCI from operating room experience, and as hardware becomes more affordable, ICU adoption will accelerate. By 2030, TCI is likely to be standard for ICU sedation at advanced centers.

The Evidence: Why Guidelines Are Shifting

Anesthesia organizations increasingly recognize TCI as a valuable approach for TIVA:

• The European Society of Anaesthesiology and Intensive Care (ESAIC) recommends TCI as a preferred technique, particularly for patients at higher risk (elderly, cardiac disease)
• TCI is widely adopted and recommended in Europe, Australia, and parts of Asia, though not yet FDA-cleared for routine use in the United States
• Numerous studies show improved predictability and reduced variability with TCI vs. manual infusion

The evidence strongly favors TCI. Broader adoption is the challenge.

Making the Shift: Implementation Strategy

For institutions considering TCI adoption:

• Start in OR: Operating rooms have anesthesiologists with high familiarity. Demonstrated safety and efficacy here builds confidence for ICU use.
• Choose your models: Select pharmacokinetic models based on your patient population. For mixed populations, Eleveld models are safer than older alternatives.
• Invest in training: Nurses and anesthesiologists need education. Budget for this.
• Monitor and validate: Track anesthetic depth, emergence time, and adverse events. Compare to pre-TCI baseline. Publish results.
• Scale progressively: Move from voluntary adoption to institutional standard over 12-24 months.